Elimination mechanisms of therapeutic monoclonal antibodies (Q28297407)

Monoclonal antibodies market

Europe PubMed Central

title

Elimination mechanisms of therapeutic monoclonal antibodies (English)

0 references

1 reference

1 reference

Mohammad A Tabrizi

1

0 references

Chih-Ming L Tseng

series ordinal

2

0 references

Lorin K Roskos

series ordinal

3

0 references

language of work or name

English

0 references

publication date

January 2006

0 references

published in

Drug Discovery Today

0 references

volume

11

0 references

issue

1-2

0 references

page(s)

81-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Pharmacokinetic aspects of biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Molecular basis of Fc receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

The transmission of immunity from mother to young and the catabolism of immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Transcytosis and catabolism of antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Engineered human IgG antibodies with longer serum half-lives in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

1 reference

7 January 2021

Clinical relevance of Fc gamma receptor polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Human antibody-Fc receptor interactions illuminated by crystal structures

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

1 reference

7 January 2021

Monoclonal antibody therapies-a 'constant' threat to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Engineered antibodies with increased activity to recruit complement

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Engineering therapeutic antibodies for improved function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Antibody humanization: a case of the 'Emperor's new clothes'?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Idiotypic-anti-idiotypic complexes and their in vivo metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903638-X

7 January 2021